CoChat

Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 + conventional dendritic cells

Open access

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Abstract

Background Type 1 conventional dendritic cells (cDC1s) possess efficient antigen presentation and cross-presentation activity, as well as potent T cell priming ability. Tissue-resident cDC1s (CD103 + cDC1s in mice, CD141 + cDC1s in humans) are linked with improved tumor control, yet the efficacy of immunotherapy using this population is understudied. Methods We generated murine CD103 + cDC1s in vitro and examined their expression of cDC1-related factors, antigen cross-presentation activity, and accumulation in tumor-draining lymph nodes (TdLNs). The antitumor efficacy of the in vitro-generated CD103 + cDC1s was studied in murine melanoma and osteosarcoma models. We evaluated tumor responses on vaccination with CD103 + cDC1s, compared these to vaccination with monocyte-derived DCs (MoDCs), tested CD103 + cDC1 vaccination with checkpoint blockade, and examined the antimetastatic activity of CD103 + cDC1s. Results In vitro-generated CD103 + cDC1s produced cDC1-associated factors such as interleukin-12p70 and CXCL10, and demonstrated antigen cross-presentation activity on stimulation with the toll-like receptor 3 agonist polyinosinic:polycytidylic acid (poly I:C). In vitro-generated CD103 + cDC1s also migrated to TdLNs following poly I:C treatment and intratumoral delivery. Vaccination with poly I:C-activated and tumor antigen-loaded CD103 + cDC1s enhanced tumor infiltration of tumor antigen-specific and interferon-γ + CD8 + T cells, and suppressed melanoma and osteosarcoma growth. CD103 + cDC1s showed superior antitumor efficacy compared with MoDC vaccination, and led to complete regression of 100% of osteosarcoma tumors in combination with CTLA-4 antibody-mediated checkpoint blockade. In vitro-generated CD103 + cDC1s effectively protected mice from pulmonary melanoma and osteosarcoma metastases. Conclusions Our data indicate an in vitro-generated CD103 + cDC1 vaccine elicits systemic and long-lasting tumor-specific T cell-mediated cytotoxicity, which restrains primary and metastatic tumor growth. The CD103 + cDC1 vaccine was superior to MoDCs and enhanced response to immune checkpoint blockade. These results indicate the potential for new immunotherapies based on use of cDC1s alone or in combination with checkpoint blockade.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2019-000474

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Anti-tumor efficacy of the CD103+ cDC1 vaccine in murine melanoma. (A) Proportion of CD103+ cDC1s 14 days following BM culture initiation. (B) Cross-presentation ability of CD103+ cDC1s in vitro, as assessed by cocultures with CFSE-labeled naïve OT-I CD8+ T cells and flow cytometry. CD103+ cDC1s were stimulated with poly I:C (20 µg/mL), 5% XG-3 supernatant, and OVA (100 ug/mL), as indicated, prior to coculturing with FACS-purified CD8+ T cells, n=2 per group. (C) Cytokine and chemokine expression by activated CD103+ cDC1s in vitro, determined by multiplex analysis of CD103+ cDC1 culture supernatant 18 hours after stimulation with 20 µg/mL poly I:C or PBS, as indicated. n=3 per group. (D) Mice with B16-OVA tumors were vaccinated i.t. on days 4-7 with CD103+ cDC1s or PBS; CD103+ cDC1s were pretreated with poly I:C (pI:C cDC1) or poly I:C+OVA (pI:C+OVA cDC1), as indicated. Tumor size was measured over time. n=11 (PBS), n=19 (pI:C cDC1), n=23 (pI:C+OVA cDC1). (E, F) The percentage (E) and absolute number (F) of IFN-γ+ CD8+ T cells in TdLNs of CD103+ cDC1 vaccinated mice or PBS controls. (E) Representative flow plots (left) and cumulative data (right). Immune profiles were determined from mice euthanized when tumors reached maximum burden. (G) Tumor-infiltrating CD8+ T cells, determined in mice vaccinated with CD103+ cDC1s or PBS at maximum tumor burden. (H) Tumor sizes in mice bearing bilateral B16-OVA tumors, vaccinated i.t. on day 4 with poly I:C activated and OVA-pulsed CD103+ cDC1s or PBS on the left side. Sizes of treated (T) and untreated (NT) tumors were determined, as indicated. n=9 (PBS), n=8 (CD103+ cDC1). (I) Survival of mice bearing bilateral tumors, treated with CD103+ cDC1 vaccine or PBS, as indicated. n=11 (PBS), n=13 (CD103+ cDC1 vaccine). (B, D–H) data shown as mean±SEM. (A-I) Results from 2 to 3 independent experiments. Data were analysed by one-way ANOVA (B, E-G), two-way ANOVA (D, H), and log-rank (Mantel-Cox) test (I). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. ANOVA, analysis of variance; BM, bone marrow; CFSE, carboxyfluorescein succinimidyl ester; cDC1, type 1 conventional dendritic cell; FACS, fluorescence-activated cell sorting; IFN-γ, interferon-γ; TdLNs, tumor-draining lymph nodes; OVA, ovalbumin.
Figure 1 Anti-tumor efficacy of the CD103+ cDC1 vaccine in murine melanoma. (A) Proportion of CD103+ cDC1s 14 days following BM culture initiation. (B) Cross-presentation ability of CD103+ cDC1s in vitro, as assessed by cocultures with CFSE-labeled naïve OT-I CD8+ T cells and flow cytometry. CD103+ cDC1s were stimulated with poly I:C (20 µg/mL), 5% XG-3 supernatant, and OVA (100 ug/mL), as indicated, prior to coculturing with FACS-purified CD8+ T cells, n=2 per group. (C) Cytokine and chemokine expression by activated CD103+ cDC1s in vitro, determined by multiplex analysis of CD103+ cDC1 culture supernatant 18 hours after stimulation with 20 µg/mL poly I:C or PBS, as indicated. n=3 per group. (D) Mice with B16-OVA tumors were vaccinated i.t. on days 4-7 with CD103+ cDC1s or PBS; CD103+ cDC1s were pretreated with poly I:C (pI:C cDC1) or poly I:C+OVA (pI:C+OVA cDC1), as indicated. Tumor size was measured over time. n=11 (PBS), n=19 (pI:C cDC1), n=23 (pI:C+OVA cDC1). (E, F) The percentage (E) and absolute number (F) of IFN-γ+ CD8+ T cells in TdLNs of CD103+ cDC1 vaccinated mice or PBS controls. (E) Representative flow plots (left) and cumulative data (right). Immune profiles were determined from mice euthanized when tumors reached maximum burden. (G) Tumor-infiltrating CD8+ T cells, determined in mice vaccinated with CD103+ cDC1s or PBS at maximum tumor burden. (H) Tumor sizes in mice bearing bilateral B16-OVA tumors, vaccinated i.t. on day 4 with poly I:C activated and OVA-pulsed CD103+ cDC1s or PBS on the left side. Sizes of treated (T) and untreated (NT) tumors were determined, as indicated. n=9 (PBS), n=8 (CD103+ cDC1). (I) Survival of mice bearing bilateral tumors, treated with CD103+ cDC1 vaccine or PBS, as indicated. n=11 (PBS), n=13 (CD103+ cDC1 vaccine). (B, D–H) data shown as mean±SEM. (A-I) Results from 2 to 3 independent experiments. Data were analysed by one-way ANOVA (B, E-G), two-way ANOVA (D, H), and log-rank (Mantel-Cox) test (I). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. ANOVA, analysis of variance; BM, bone marrow; CFSE, carboxyfluorescein succinimidyl ester; cDC1, type 1 conventional dendritic cell; FACS, fluorescence-activated cell sorting; IFN-γ, interferon-γ; TdLNs, tumor-draining lymph nodes; OVA, ovalbumin.CC BY-NC · PubMed Central
Figure 2 Comparison of CD103+ cDC1 and MoDC vaccine activity in melanoma. (A–C) Animals with bilateral B16-OVA tumors were vaccinated with CD103+ cDC1s or MoDCs at 4 and 7 days following tumor establishment. Prior to DC injection, cells were incubated with GM-CSF (20 ng/mL) and OVA (400 µg/mL). CD103+ cDC1s were stimulated with poly I:C (20 µg/mL) and MoDCs were stimulated with LPS (100 ng/mL). Animals were vaccinated on the left-side tumor (circle with arrow); the distal right-side tumor was untreated (circle without arrow), as indicated (A). Sizes of vaccinated B16-OVA (treated, (T)) tumors and distal untreated (NT) tumors over time, as indicated (B). Survival of mice bearing bilateral tumors, following treatment with CD103+ cDC1 vaccine, MoDC vaccine, or PBS on one side, as indicated (C). n=10 for each group. (D–I) CD45.1+ CD103+ cDC1s or CD45.1+ MoDCs were injected into the left-side tumor of CD45.2+ mice bearing bilateral B16-OVA tumors, using 1×107 DCs/animal, 4 days following tumor implantation. After 40 hours, the amounts of CD45.1+ CD11c+ CD103+ CD11b- cDC1s (CD103+ cDC1s) (D–F) and CD45.1+ CD11c+ CD103- CD11b+ MoDCs (G–I) were determined in tumors and TdLNs; n=5 per group. (J, K) Proliferation (J) and survival (K) of DC vaccines prior to i.t. delivery, or 40 hours following vaccination (n=6–7), as indicated. (B, D, E, G, H, K) Data shown as mean±SEM. (A–K) Results from two independent experiments. Data were analysed by unpaired Student’s t-test (K), one-way ANOVA (D, E, G, H), two-way ANOVA (B), or log-rank (Mantel-Cox) test (C). **P<0.01, ***P<0.001, ****P<0.0001. ANOVA, analysis of variance; cDC1, type 1 conventional dendritic cell; DC, dendritic cell; i.t., intratumoral; MoDC, monocyte-derived dendritic cell; TdLNs, tumor-draining lymph nodes; OVA, ovalbumin.
Figure 2 Comparison of CD103+ cDC1 and MoDC vaccine activity in melanoma. (A–C) Animals with bilateral B16-OVA tumors were vaccinated with CD103+ cDC1s or MoDCs at 4 and 7 days following tumor establishment. Prior to DC injection, cells were incubated with GM-CSF (20 ng/mL) and OVA (400 µg/mL). CD103+ cDC1s were stimulated with poly I:C (20 µg/mL) and MoDCs were stimulated with LPS (100 ng/mL). Animals were vaccinated on the left-side tumor (circle with arrow); the distal right-side tumor was untreated (circle without arrow), as indicated (A). Sizes of vaccinated B16-OVA (treated, (T)) tumors and distal untreated (NT) tumors over time, as indicated (B). Survival of mice bearing bilateral tumors, following treatment with CD103+ cDC1 vaccine, MoDC vaccine, or PBS on one side, as indicated (C). n=10 for each group. (D–I) CD45.1+ CD103+ cDC1s or CD45.1+ MoDCs were injected into the left-side tumor of CD45.2+ mice bearing bilateral B16-OVA tumors, using 1×107 DCs/animal, 4 days following tumor implantation. After 40 hours, the amounts of CD45.1+ CD11c+ CD103+ CD11b- cDC1s (CD103+ cDC1s) (D–F) and CD45.1+ CD11c+ CD103- CD11b+ MoDCs (G–I) were determined in tumors and TdLNs; n=5 per group. (J, K) Proliferation (J) and survival (K) of DC vaccines prior to i.t. delivery, or 40 hours following vaccination (n=6–7), as indicated. (B, D, E, G, H, K) Data shown as mean±SEM. (A–K) Results from two independent experiments. Data were analysed by unpaired Student’s t-test (K), one-way ANOVA (D, E, G, H), two-way ANOVA (B), or log-rank (Mantel-Cox) test (C). **P<0.01, ***P<0.001, ****P<0.0001. ANOVA, analysis of variance; cDC1, type 1 conventional dendritic cell; DC, dendritic cell; i.t., intratumoral; MoDC, monocyte-derived dendritic cell; TdLNs, tumor-draining lymph nodes; OVA, ovalbumin.CC BY-NC · PubMed Central
Figure 3 Immune responses elicited by CD103+ cDC1 and MoDC vaccines in melanoma. Mice bearing bilateral B16-OVA tumors were vaccinated on one side with CD103+ cDC1s, MoDCs, or PBS as described in the legend to figure 2. (A–C) The number of tumor-infiltrating CD8+ T cells (A), and numbers and proportions of OVA-specific CD8+ T cells in tumors (B, C) were determined 14 days following vaccination in tumors that received the DC vaccine (treated, (T)) and in distal untreated (NT) tumors, as indicated. (D) The ability of vaccine-derived CD45.1+ CD103+ cDC1s or CD45.1+ MoDCs, purified 40 hours following i.t. delivery, to stimulate OT-I CD8+ T cell proliferation was determined in coculture assays in vitro. Proliferating OT-I CD8+ T cells were measured at 72 hours; assays were performed in the presence of 20 ng/mL GM-CSF. (E–G) The numbers of CD4+ T cells (E), CD4+ CD25+ Foxp3+ Treg (F), and CD4+ Foxp3- effector T cells (Teff) (G) were determined 14 days following vaccination in tumors that received the DC vaccine (treated, (T)) and in distal untreated (NT) tumors, as indicated. (H) The percentage of Tregs within the total CD4+ T cell population in tumors from mice vaccinated as indicated, 14 days following vaccination. (I) The ability of vaccine-derived CD45.1+ CD103+ cDC1s or CD45.1+ MoDCs, purified from tumors 40 hours following i.t. delivery, to stimulate OT-II CD4+ T cell proliferation was determined in coculture assays in vitro. Proliferating OT-II CD4+ T cells were measured at 72 hours; assays were performed in the presence of 20 ng/mL GM-CSF. (A, B, D–I) Data shown as mean±SEM. (A–I) Representative (C) or cumulative (A, B, D–I) results from two independent experiments; n=9 (PBS), n=5 (MoDC), n=4 (CD103+ cDC1). Results were analysed by one-way ANOVA. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. ANOVA, analysis of variance; cDC1, type 1 conventional dendritic cells; i.t., intratumoral; MoDC, monocyte-derived dendritic cell; OVA, ovalbumin.
Figure 3 Immune responses elicited by CD103+ cDC1 and MoDC vaccines in melanoma. Mice bearing bilateral B16-OVA tumors were vaccinated on one side with CD103+ cDC1s, MoDCs, or PBS as described in the legend to figure 2. (A–C) The number of tumor-infiltrating CD8+ T cells (A), and numbers and proportions of OVA-specific CD8+ T cells in tumors (B, C) were determined 14 days following vaccination in tumors that received the DC vaccine (treated, (T)) and in distal untreated (NT) tumors, as indicated. (D) The ability of vaccine-derived CD45.1+ CD103+ cDC1s or CD45.1+ MoDCs, purified 40 hours following i.t. delivery, to stimulate OT-I CD8+ T cell proliferation was determined in coculture assays in vitro. Proliferating OT-I CD8+ T cells were measured at 72 hours; assays were performed in the presence of 20 ng/mL GM-CSF. (E–G) The numbers of CD4+ T cells (E), CD4+ CD25+ Foxp3+ Treg (F), and CD4+ Foxp3- effector T cells (Teff) (G) were determined 14 days following vaccination in tumors that received the DC vaccine (treated, (T)) and in distal untreated (NT) tumors, as indicated. (H) The percentage of Tregs within the total CD4+ T cell population in tumors from mice vaccinated as indicated, 14 days following vaccination. (I) The ability of vaccine-derived CD45.1+ CD103+ cDC1s or CD45.1+ MoDCs, purified from tumors 40 hours following i.t. delivery, to stimulate OT-II CD4+ T cell proliferation was determined in coculture assays in vitro. Proliferating OT-II CD4+ T cells were measured at 72 hours; assays were performed in the presence of 20 ng/mL GM-CSF. (A, B, D–I) Data shown as mean±SEM. (A–I) Representative (C) or cumulative (A, B, D–I) results from two independent experiments; n=9 (PBS), n=5 (MoDC), n=4 (CD103+ cDC1). Results were analysed by one-way ANOVA. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. ANOVA, analysis of variance; cDC1, type 1 conventional dendritic cells; i.t., intratumoral; MoDC, monocyte-derived dendritic cell; OVA, ovalbumin.CC BY-NC · PubMed Central
Figure 4 Efficacy of the CD103+ cDC1 vaccine in metastatic melanoma. (A) Schematic diagram of the experimental approach. (B, C) Representative image (B) and quantification (C) of lung melanoma foci following treatment with poly I:C+OVA-stimulated CD103+ cDC1 vaccine or PBS and challenge with B16-OVA cells i.v., as indicated. n=5 (PBS), n=6 (CD103+ cDC1 vaccine). (D–F) Percentages (D) and absolute numbers (E and F) of donor CD45.1+ IFN-γ+ CD8+ T cells and endogenous CD45.1- IFN-γ+ CD8+ T cells in the spleen of mice treated with CD103+ cDC1 vaccine or PBS. (G, H) Percentages (G) and absolute numbers (H) of splenic Th1, Th2, Th17, and Treg subsets. (B–H) Results from animals 14 days after challenge with B16-OVA cells i.v. Data shown as mean±SEM, from two independent experiments. Results were analysed by unpaired Student’s t-test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. cDC1, type 1 conventional dendritic cells; IFN-γ, interferon-γ; OVA, ovalbumin; Th1, T helper 1; Th2, T helper 2; Th17, interleukin-17-positive T cells; Treg, T regulatory cells.
Figure 4 Efficacy of the CD103+ cDC1 vaccine in metastatic melanoma. (A) Schematic diagram of the experimental approach. (B, C) Representative image (B) and quantification (C) of lung melanoma foci following treatment with poly I:C+OVA-stimulated CD103+ cDC1 vaccine or PBS and challenge with B16-OVA cells i.v., as indicated. n=5 (PBS), n=6 (CD103+ cDC1 vaccine). (D–F) Percentages (D) and absolute numbers (E and F) of donor CD45.1+ IFN-γ+ CD8+ T cells and endogenous CD45.1- IFN-γ+ CD8+ T cells in the spleen of mice treated with CD103+ cDC1 vaccine or PBS. (G, H) Percentages (G) and absolute numbers (H) of splenic Th1, Th2, Th17, and Treg subsets. (B–H) Results from animals 14 days after challenge with B16-OVA cells i.v. Data shown as mean±SEM, from two independent experiments. Results were analysed by unpaired Student’s t-test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. cDC1, type 1 conventional dendritic cells; IFN-γ, interferon-γ; OVA, ovalbumin; Th1, T helper 1; Th2, T helper 2; Th17, interleukin-17-positive T cells; Treg, T regulatory cells.CC BY-NC · PubMed Central
Figure 5 Response of K7M3 primary and metastatic osteosarcoma to the CD103+ cDC1 vaccine. (A, B) Tumor size (A) and survival rate (B) of Balb/c mice following vaccination at 4 and 7 days after tumor inoculation with CD103+ cDC1s or PBS (control). CD103+ cDC1s were pretreated with poly I:C (pI:C cDC1) or poly I:C+K7M3 osteosarcoma cell lysate (pI:C+OS lysate cDC1), as indicated; n=6 per group. Surviving mice were challenged with K7M3 cells on day 100 (dotted line), without receiving additional therapy (B). Cumulative survival curves shown. (C) T cell infiltration in osteosarcoma tumors in CD103+ cDC1 vaccine-treated mice (n=4) or PBS treated controls (n=6). Immune profiles were determined from mice euthanized when tumors reached maximum burden. (D) Schematic diagram of experimental metastasis approach. (E) Representative lung metastases as assessed by H&E staining. (F–J) Quantification of visible metastatic foci (F), lung weight (G), tumor area (H), lung necrotic area (I), and the ratio of tumor area to total area of the lung (J), 28 days after delivery of K7M3 cells i.v. (A, C, F–J). Data shown as mean±SEM. (A–J) Results from two independent experiments. Results were analysed by two-way ANOVA (A), log-rank (Mantel-Cox) test (B), and unpaired Student’s t-test (C, F–J). *P<0.05, **P<0.01, ****P<0.0001. ANOVA, analysis of variance; cDC1, type 1 conventional dendritic cells.
Figure 5 Response of K7M3 primary and metastatic osteosarcoma to the CD103+ cDC1 vaccine. (A, B) Tumor size (A) and survival rate (B) of Balb/c mice following vaccination at 4 and 7 days after tumor inoculation with CD103+ cDC1s or PBS (control). CD103+ cDC1s were pretreated with poly I:C (pI:C cDC1) or poly I:C+K7M3 osteosarcoma cell lysate (pI:C+OS lysate cDC1), as indicated; n=6 per group. Surviving mice were challenged with K7M3 cells on day 100 (dotted line), without receiving additional therapy (B). Cumulative survival curves shown. (C) T cell infiltration in osteosarcoma tumors in CD103+ cDC1 vaccine-treated mice (n=4) or PBS treated controls (n=6). Immune profiles were determined from mice euthanized when tumors reached maximum burden. (D) Schematic diagram of experimental metastasis approach. (E) Representative lung metastases as assessed by H&E staining. (F–J) Quantification of visible metastatic foci (F), lung weight (G), tumor area (H), lung necrotic area (I), and the ratio of tumor area to total area of the lung (J), 28 days after delivery of K7M3 cells i.v. (A, C, F–J). Data shown as mean±SEM. (A–J) Results from two independent experiments. Results were analysed by two-way ANOVA (A), log-rank (Mantel-Cox) test (B), and unpaired Student’s t-test (C, F–J). *P<0.05, **P<0.01, ****P<0.0001. ANOVA, analysis of variance; cDC1, type 1 conventional dendritic cells.CC BY-NC · PubMed Central
Figure 6 Combination therapy with CD103+ cDC1 vaccine and immune checkpoint blockade in osteosarcoma. (A) Schematic diagram of experimental approach. (B–D) Tumor growth in individual mice (B), median tumor size (C), and survival rate (D) following CD103+ cDC1 vaccine and immune checkpoint inhibitors, as indicated. n=6–7 for each group. Data shown as mean±SEM, from two independent experiments. Results were analysed by two-way ANOVA (C) and log-rank (Mantel-Cox) test (D). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. ANOVA, analysis of variance.
Figure 6 Combination therapy with CD103+ cDC1 vaccine and immune checkpoint blockade in osteosarcoma. (A) Schematic diagram of experimental approach. (B–D) Tumor growth in individual mice (B), median tumor size (C), and survival rate (D) following CD103+ cDC1 vaccine and immune checkpoint inhibitors, as indicated. n=6–7 for each group. Data shown as mean±SEM, from two independent experiments. Results were analysed by two-way ANOVA (C) and log-rank (Mantel-Cox) test (D). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. ANOVA, analysis of variance.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 117

Metadata

Authors
Zhou, Y., Slone, N., Chrisikos, T. T., Kyrysyuk, O., Babcock, R. L., Medik, Y. B., Li, H. S., Kleinerman, E. S., & Watowich, S. S.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Watowich, Stephanie S
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-04
Volume
8
Issue
1
Pages
e000474
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3015270738
Cited by
112
References
48
Citations by year
2026: 9 · 2025: 26 · 2024: 14 · 2023: 22 · 2022: 22 · 2021: 11 · 2020: 7
FWCI
5.43
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute of Allergy and Infectious Diseases (3R01AI109294-04S1, R01AI109294)
  • Cancer Prevention and Research Institute of Texas (RP170067)
  • National Cancer Institute (P30CA016672)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
dendritic cell vaccine, cancer immunotherapy, cross-presentation, tumor-draining lymph nodes, melanoma, osteosarcoma, metastasis, CTLA-4 blockade, immune checkpoint blockade, monocyte-derived dendritic cells, IL-12, CXCL10, tumor-specific T cells, poly(I:C)
MeSH terms
Animals, Antigens, Neoplasm, Bone Neoplasms, Dendritic Cells, Immunotherapy, Lung Neoplasms, Melanoma, Experimental, Mice, Inbred C57BL, Sarcoma, Experimental, Osteosarcoma, Tumor Cells, Cultured, Vaccines, Antigens, CD, Antigen Presentation, Integrin alpha Chains, Cross-Priming, Mice, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.